^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Small Lymphocytic Lymphoma
    Drug:Imbruvica (ibrutinib) (BTK inhibitor) +
    Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    04/21/2020
    Excerpt:
    For CLL/SLL, IMBRUVICA can be administered as a single agent, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab (BR).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL without del(17p)/TP53 mutation…FIRST-LINE THERAPY…Other recommended regimens…Ibrutinib + rituximab (category 2B)...